Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kirby Institute
With
The University of New South Wales
The study aims are:
1. To evaluate the effect of successful prior treatment or spontaneous clearance of recently acquired HCV infection on long-term quality of life, social functioning, injecting behaviour, mental health and liver health.
2. To assess the incidence of HCV re-infection following prior treatment induced clearance or spontaneous clearance of recently acquired chronic HCV infection.
3. To determine predictors of HCV re-infection following recently acquired HCV infection treatment.
4. To determine frequency and predictors of new mixed and superinfections in ATAHC subjects with persistent viraemia.
5. To add to a tissue repository of serum and PBMCs from well-characterised patients treated for recently acquired HCV infection to allow future examination of the role of other variables that may potentially impact on the prognosis and outcomes of early HCV treatment.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previous enrolment in the Australian Trial of Acute Hepatitis C Virus Infection (ATAHC) Study.
Provision of written, informed consent.
You may not be if
In the opinion of the investigator that the patient is not able to provide informed consent.
Inability or unwillingness to comply with study collection requirements.